Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* COZADD BRUCE C						2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]								heck all a	nip of Reporti oplicable) ector icer (give title	r 10		vner	
(Last) (First) (Middle) 5TH FL, WATERLOO EXCHANGE WATERLOO RD						3. Date of Earliest Transaction (Month/Day/Year) 05/02/2022								X Officer (give title Other (specify below) Chairman & CEO					
(Street) DUBLIN 4 L2					= 4. If	Line) X Fo										al or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					tion	2A. I Exec if an	ZA. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		(A) or	5. A Sec Bei	mount of urities eficially aed Following	Forr (D) (n: Direct or Indirect	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Tra	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Ordinary	05/02/2	05/02/2022						9,700	A	\$46.8	6.83 355,70			D					
Ordinary Shares 05/0					2022				S ⁽¹⁾		1,600	D	\$155.3	4 ⁽²⁾	354,162		D		
Ordinary Shares 05					/02/2022				S ⁽¹⁾		3,177	D	\$156.1	3(3)	350,985		D		
Ordinary Shares 05					2/2022				S ⁽¹⁾		767	D	\$156.9	7 ⁽⁴⁾	350,218		D		
Ordinary Shares 05/02/					2022				S ⁽¹⁾		716	D	\$158.5	3 ⁽⁵⁾	349,502		D		
Ordinary Shares 05/02/2					2022	022					1,000	D	\$158.0	57	348,502		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date,	4. Transa	4. Transaction Code (Instr.		5. Number of			isable and	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price Deriva Securii (Instr. 9	ve derivativ	re es ally ig d tion(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option (right to buy)	\$46.83	05/02/2022			M ⁽⁶⁾			9,700	(7)		08/08/2022	Ordinary Shares	9,700	\$0.0	29,0	32	D		

Explanation of Responses:

- 1. Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
- 2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$154.77 to \$155.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales
- 3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$155.79 to \$156.57. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales
- 4. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from \$156.84 to \$157.11 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales
- 5. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from \$157.885 to \$158.67. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- 6. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 7. This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.

By: /s/Paz Dizon, as attorney in 05/04/2022 fact For: Bruce C Cozadd

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.